Phase 3 and case-matching studies evaluating effect of erythropoiesis-stimulating agent (ESA) treatment on disease outcome in lower-risk myelodysplastic syndrome (MDS).
| Author . | Study design . | Cohorts . | No. patients . | Erythroid response . | AML transformation . | Overall survival . |
|---|---|---|---|---|---|---|
| *Comparison of overall survival in ESA responders versus non-responders and controls. | ||||||
| Abbrevations: NA, not available; SC, supportive care; mos, months; HR, Hazard ratio. | ||||||
| Miller et al14 | Phase 3, crossover | ESA, SC | 105 | 35%, 9% P=.002 | 0%, 3.6% | Median 53 mos vs 26 mos; P=.009* |
| Jadersten et al21 | Case matching | ESA, Control | 129 363 | 41% NA | HR=0.39, P=.001 | HR=0.44, P<.001* |
| Park et al22 | Case matching | ESA, IPSS/IMRAW | 284 447 | NA | 8% at 5 y, HR=0.2 vs 16%; P=.0002 | 82% at 5 y, HR=0.3 vs 47% P<.0001 |
| Author . | Study design . | Cohorts . | No. patients . | Erythroid response . | AML transformation . | Overall survival . |
|---|---|---|---|---|---|---|
| *Comparison of overall survival in ESA responders versus non-responders and controls. | ||||||
| Abbrevations: NA, not available; SC, supportive care; mos, months; HR, Hazard ratio. | ||||||
| Miller et al14 | Phase 3, crossover | ESA, SC | 105 | 35%, 9% P=.002 | 0%, 3.6% | Median 53 mos vs 26 mos; P=.009* |
| Jadersten et al21 | Case matching | ESA, Control | 129 363 | 41% NA | HR=0.39, P=.001 | HR=0.44, P<.001* |
| Park et al22 | Case matching | ESA, IPSS/IMRAW | 284 447 | NA | 8% at 5 y, HR=0.2 vs 16%; P=.0002 | 82% at 5 y, HR=0.3 vs 47% P<.0001 |